Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates
dc.contributor.author | González Arceo, Maitane | |
dc.contributor.author | Gómez López, Iván | |
dc.contributor.author | Carr Ugarte, Helen | |
dc.contributor.author | Eseberri Barace, Itziar | |
dc.contributor.author | González, Marcela | |
dc.contributor.author | Cano, M. Pilar | |
dc.contributor.author | Portillo Baquedano, María Puy | |
dc.contributor.author | Gómez Zorita, Saioa | |
dc.date.accessioned | 2023-01-13T17:36:13Z | |
dc.date.available | 2023-01-13T17:36:13Z | |
dc.date.issued | 2022-12-24 | |
dc.identifier.citation | International Journal of Molecular Sciences 24(1) : (2023) // Article ID 299 | es_ES |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | http://hdl.handle.net/10810/59288 | |
dc.description.abstract | Isorhamnetin is a plant-derived secondary metabolite which belongs to the family of flavonoids. This review summarises the main outcomes described in the literature to date, regarding the effects of isorhamnetin on obesity from in vitro and in vivo studies. The studies carried out in pre-adipocytes show that isorhamnetin is able to reduce adipogenesis at 10 μM or higher doses and that these effects are mediated by Pparγ and by Wnt signalling pathway. Very few studies addressed in rodents are available so far. It seems that treatment periods longer than two weeks are needed by isorhamnetin and its glycosides to be effective as anti-obesity agents. Nevertheless, improvements in glycaemic control can be observed even in short treatments. Regarding the underlying mechanisms of action, although some contradictory results have been found, reductions in de novo lipogenesis and fatty acid uptake could be proposed. Further research is needed to increase the scientific evidence referring to this topic; studies in animal models are essential, as well as randomised clinical trials to determine whether the positive results observed in animals could also be found in humans, in order to determine if isorhamnetin and its glycosides can represent a real tool against obesity. | es_ES |
dc.description.sponsorship | This study was supported by the Instituto de Salud Carlos III (CIBERobn) under Grant CB12/03/30007 and the Ministerio de Ciencia e Innovación (PID2020-118300RB-C21 and PID2020-118300RB-C22 co-funded by FEDER). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2020-118300RB-C21 | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2020-118300RB-C22 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | isorhamnetin | es_ES |
dc.subject | isorhamnetin glucosides | es_ES |
dc.subject | obesity | es_ES |
dc.subject | adipose tissue | es_ES |
dc.subject | adipocytes | es_ES |
dc.subject | animal models | es_ES |
dc.title | Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2023-01-06T13:52:41Z | |
dc.rights.holder | © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/24/1/299 | es_ES |
dc.identifier.doi | 10.3390/ijms24010299 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | |
dc.departamentoeu | Farmazia eta elikagaien zientziak |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).